ANNOUNCEMENT
ISPOR “ON THE ROAD” IN 1ST QUARTER 2016
Princeton, NJ—April 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (
ISPOR) attended a number of industry meetings during the first quarter of 2016. The following is a sampling of ISPOR’s meeting activity.
EUnetHTA Joint Action 3 Kick-Off Meeting
The European Network for Health Technology Assessment (
EUnetHTA) held its
Joint Action 3 (JA3) kick-off meeting on March 3, 2016. EUnetHTA JA3 will begin its activities in the near future with the objective to increase the use, quality, and efficiency of joint HTA work at the European level. ISPOR’s CEO, Nancy Berg, and Senior Director of Scientific and Health Policy Initiatives, Nadia Naaman, attended the meeting.
Patients as Partners Conference
ISPOR’s Manager of Scientific and Health Policy Initiatives, Theresa Tesoro, MSN, attended the
3rd Annual Patients as Partners Conference held in Philadelphia, PA, USA on March 2-3, 2016. Attendance of this conference helps to support development of ISPOR’s patient initiatives.
FDAMA 114 Discussion Meeting
ISPOR President, Daniel C. Malone, RPh, PhD, attended and participated in the panel of the Food and Drug Administration Modernization Act (FDAMA) Section 114 discussion meeting in Washington, DC, USA this March. ISPOR’s Strategic Plan pillar focused on Scientific and Research Excellence calls for ISPOR to act as an educational resource to policy-makers, such as FDA.
Pan American Health Organization (PAHO) Discussion
ISPOR CEO, Nancy Berg, attended discussions at the
PAHO Washington, DC, USA office. Relationships with organizations that have similar interests, such as PAHO, support ISPOR’s Strategic Plan pillar focused on Communication and Collaboration.
For additional information, please contact Betsy Lane, director, chief marketing and communications officer at
BLane@ispor.org or 609-586-4981 x112.
###